Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia

Overview of attention for article published in Annals of Hematology, August 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 27 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,636 followers.

Research from China: Sequential Treatment Combining Cladribine-Based Re-Induction, Myeloablative Allogeneic HSCT, & Prophylactic Donor Lymphocyte Infusion: A Promising Treatment for Refractory Acute Myeloid Leukemia https://t.co/o1OKXduMSs

14 Aug 2018

Reply Repost Favourite

Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia." https://t.co/nRdRP6M9I0

09 Aug 2018

Reply Repost Favourite

06 Aug 2018

Reply Repost Favourite